ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial data

• Published in: Journal of human hypertension Vol. 27; no. 8; pp. 492 - 496
• Main Authors: Prieto-Merino, D, Dobson, J, Gupta, A K, Chang, C-L, Sever, P S, Dahlöf, B, Wedel, H, Pocock, S, Poulter, N
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.08.2013; Nature Publishing Group
• Subjects: 692/699/75/243; 692/700/1750; Adult; Aged; Blood pressure; Cardiovascular diseases; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - etiology; Cerebral infarction; Cholesterol; Clinical Medicine; Creatinine; Diabetes mellitus; Epidemiology; Female; Health Administration; Health risk assessment; Health Status Indicators; High density lipoprotein; Humans; Hypertension; Hypertension - complications; Klinisk medicin; Male; Medicine; Medicine & Public Health; Middle Aged; Myocardial infarction; original-article; Patients; Public Health; Risk Assessment; Risk Factors; primary prevention; risk factors; cardiovascular diseases; risk score
• ISSN: 0950-9240; 1476-5527; 1476-5527
• DOI: 10.1038/jhh.2013.3

A number of risk scores already exist to predict cardiovascular (CV) events. However, scores developed with data collected some time ago might not accurately predict the CV risk of contemporary hypertensive patients that benefit from more modern treatments and management. Using data from the randomised clinical trial Anglo-Scandinavian Cardiac Outcomes Trial-BPLA, with 15 955 hypertensive patients without previous CV disease receiving contemporary preventive CV management, we developed a new risk score predicting the 5-year risk of a first CV event (CV death, myocardial infarction or stroke). Cox proportional hazard models were used to develop a risk equation from baseline predictors. The final risk model (ASCORE) included age, sex, smoking, diabetes, previous blood pressure (BP) treatment, systolic BP, total cholesterol, high-density lipoprotein–cholesterol, fasting glucose and creatinine baseline variables. A simplified model (ASCORE-S) excluding laboratory variables was also derived. Both models showed very good internal validity. User-friendly integer score tables are reported for both models. Applying the latest Framingham risk score to our data significantly overpredicted the observed 5-year risk of the composite CV outcome. We conclude that risk scores derived using older databases (such as Framingham) may overestimate the CV risk of patients receiving current BP treatments; therefore, ‘updated’ risk scores are needed for current patients.